NCT00039468View on ClinicalTrials.gov

Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

September 30, 2007

Study Completion Date

February 29, 2008

Conditions
Brain and Central Nervous System Tumors
Interventions
DRUG

irinotecan hydrochloride

350 or 700 mg/m2 IV every 3 weeks

DRUG

thalidomide

400mg/day oral

Trial Locations (2)

03756-0002

Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon

43210-1240

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University, Columbus

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Dartmouth-Hitchcock Medical Center

OTHER

NCT00039468 - Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy | Biotech Hunter | Biotech Hunter